logo BDSP

Base documentaire


  1. Economic impact of immunization against rotavirus gastroenteritis : evidence from a clinical trial.

    Article - En anglais

    Objective 

    To estimate the economic impact of immunization against rotavirus gastroenteritis in an infant population in the United States.

    Design 

    Cost identification and break-even analyses from the perspective of society, nested within a phase 3, randomized, double-blind, placebo-controlled trial.

    Patients 

    Infants (N=1278), aged 6 to 22 weeks, enrolled during the summer and fall of 1991 and followed up until July 1,1992.

    Intervention 

    Immunization schedule of three doses of orally administered tetravalent or serotype I rhesus rotavirus vaccine, or placebo.

    Main Outcome Measures 

    Incidence of rotavirus gastroenteritis, total direct medical costs, direct nonmedical costs, and indirect costs of rotavirus and nonrotavirus gastroenteritis for the duration of the study and of any illness during 5 days after each dose.

    The cost of the vaccine was not included.

    Results 

    Median total cost per infant among the 1187 infants who completed the immunization schedule was $9 in the tetravalent vaccine group, 59 in the serotype 1 vaccine group, and $49 in the placebo group (P=01).

    Rotavirus gastroenteritis occurred in 195 infants (16%) : 13% (51/398) in the tetravalent group, 12% (47/404) in the serotype 1 group, and 25% (97/385) in the placebo group (P<. 0001).

    Of infants with an episode of rotavirus gastroenteritis, the proportion who incurred cost during the episode and the median cost during the episode did not differ by treatment group.

    Mots-clés Pascal : Etats Unis, Amérique du Nord, Amérique, Analyse coût, Economie santé, Nourrisson, Homme, Virose, Infection, Diarrhée, Rotavirus humain, Rotavirus, Reoviridae, Virus, Gastroentérite, Aigu, Vaccination, Prévention, Evaluation, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie, Immunisation active

    Mots-clés Pascal anglais : United States, North America, America, Cost analysis, Health economy, Infant, Human, Viral disease, Infection, Diarrhea, Human rotavirus, Rotavirus, Reoviridae, Virus, Gastroenteritis, Acute, Vaccination, Prevention, Evaluation, Digestive diseases, Gastric disease, Intestinal disease, Active immunization

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0278092

    Code Inist : 002B05C02F. Création : 01/03/1996.